静脉-静脉体外膜氧合改善创伤合并呼吸衰竭患者的结局
该单中心倾向评分匹配队列纳入2014年1月1日至2023年10月30日创伤患者,将接受VV ECMO者与符合本机构VV ECMO指征但接受常规通气者1:1匹配。匹配后两组年龄、损伤机制、ISS、SI、乳酸、颅脑损伤频率及干预前呼吸参数相似。VV ECMO组出院生存率70% vs 常规治疗组41%(P<0.001),VV ECMO使用对应HR 0.31(95%CI 0.18-0.52;P<0.001),死亡OR 0.29(95%CI 0.14-0.58;P<0.001)。作者结论为VV ECMO可能代表经适当筛选创伤合并急性呼吸衰竭患者的安全替代治疗,但需进一步研究。
要点
- 创伤合并呼吸衰竭患者接受VV ECMO者出院生存率70%,匹配的常规通气组41%(P<0.001)。
- VV ECMO使用对应死亡HR 0.31(95%CI 0.18-0.52;P<0.001),死亡OR 0.29(95%CI 0.14-0.58;P<0.001)。
- 匹配后两组年龄、损伤机制、ISS、SI、乳酸、颅脑损伤频率及干预前pH、二氧化碳分压、氧饱和度相似。
- 作者认为VV ECMO可能为经适当筛选的创伤合并急性呼吸衰竭患者的安全替代治疗,但需进一步研究。
适用人群与场景
- 2014年1月1日至2023年10月30日单中心创伤患者,接受VV ECMO或符合本机构VV ECMO指征但接受常规通气策略者,1:1倾向评分匹配。
研究设计与关键结果
- 单中心倾向评分匹配队列:81例创伤VV ECMO患者与128例接受常规治疗者符合纳入标准,匹配后比较。
- 匹配后VV ECMO组与常规治疗组年龄、损伤机制、ISS、SI、乳酸水平及创伤性脑损伤频率相似,干预前pH、二氧化碳分压、乳酸水平及氧饱和度相似。
- 主要终点出院生存率:VV ECMO组70% vs 匹配常规治疗组41%(P<0.001)。
- VV ECMO使用对应死亡HR 0.31(95%CI 0.18-0.52;P<0.001)。
- 匹配创伤患者接受VV ECMO vs 常规治疗的死亡OR 0.29(95%CI 0.14-0.58;P<0.001)。
证据类型、等级与局限
- 证据类型:单中心倾向评分匹配队列研究。
- 局限:原文报告需进一步研究(further studies are warranted)。
对床旁实践的改变
- 作者认为,VV ECMO可能代表对经适当筛选的创伤合并急性呼吸衰竭患者的一种安全替代治疗方式,但需进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Introduction: Veno-venous extracorporeal membrane oxygenation (VV ECMO) improves hypoxemia and carbon dioxide clearance in patients with severe respiratory derangements. A greater understanding of the potential benefits of VV ECMO in trauma patients could lead to broader adoption. We hypothesize that trauma patients who receive VV ECMO have improved mortality outcomes when compared to those receiving conventional ventilator management given the rapid stabilization VV ECMO promotes. Methods: We performed a single-center, propensity score-matched cohort study. All trauma patients from January 1, 2014, to October 30, 2023, who were placed on VV ECMO or who would have met institutional guidelines for VV ECMO but were managed with conventional ventilator strategies were matched 1:1. The primary outcome analysis was survival at hospital discharge. Significance was defined as P < 0.05. Results: Eighty-one trauma VV ECMO patients and 128 patients who received conventional management met criteria for inclusion. After matching, VV ECMO and conventional treatment cohort characteristics were similar in age and mechanism of injury. Matched ISS, SI, lactate levels, and frequency of traumatically brain injured were also similar. Finally, respiratory parameters including preintervention, pH, partial pressure of carbon dioxide, lactate levels, and oxygen saturation were similar between matched groups. VV ECMO patients had higher survival rates at discharge when compared to the matched conventional treatment group (70% vs. 41%, P < 0.001). Corresponding hazard ratio for VV ECMO use was 0.31 (95% CI 0.18-0.52; P < 0.001). The odds ratio of mortality in matched trauma patients who receive VV ECMO versus conventional treatment was 0.29 (95% CI 0.14-0.58; P < 0.001). Conclusion: VV ECMO may represent a safe, alternative treatment approach for appropriately screened trauma patients with acute respiratory failure; however, further studies are warranted.
参考来源
- Powell EK, Betzold R, Lammers DT, et al. VENO-VENOUS EXTRACORPOREAL MEMBRANE OXYGENATION IMPROVES OUTCOMES IN TRAUMA PATIENTS SUFFERING RESPIRATORY FAILURE. Shock. 2024. PMID: 39456115. doi:10.1097/SHK.0000000000002491
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。